RxDoctor Payments Data

Konstantin Dzamashvili, MD

Neurology · Fort Myers, FLNPI 1174529085

Payments from drug & device makers

$17,563in general payments, 2019–2025

Across 823 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • UCB, Inc.$1K
  • AstraZeneca$962
  • Lundbeck LLC$838
  • GE HealthCare$689
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$600%
  • Food & beverage$17,490100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)97$1,761
Amgen(2 entities)70$1,472
UCB, Inc.35$1,126
AstraZeneca(2 entities)37$962
Lundbeck LLC38$838
GE HealthCare38$689
Acadia Pharmaceuticals Inc43$636
Genentech USA, Inc.28$616
Sanofi23$590
Novartis33$568
EMD Serono, Inc.20$495
Biogen25$468
Teva Pharmaceuticals USA, Inc.13$426
Lilly USA, LLC28$424
Argenx US, Inc.18$397
Eisai Inc.17$378
SK Life Science, Inc.7$346
CSL Behring13$340
Pfizer21$331
Biohaven Pharmaceutical Holding Company Ltd.17$266
Sunovion Pharmaceuticals Inc.13$254
Merz Pharmaceuticals, LLC10$249
Bristol Myers Squibb12$249
Octapharma USA, Inc.5$239
Avanir Pharmaceuticals, Inc.11$237
Otsuka America Pharmaceutical, Inc.7$231
Amneal Pharmaceuticals LLC12$230
Neurocrine Biosciences, Inc.11$213
Takeda Pharmaceuticals U.S.A., Inc.7$201
Biohaven Pharmaceuticals, Inc.11$190
Catalyst Pharmaceuticals, Inc.8$173
Adamas Pharmaceuticals, Inc.8$163
Acorda Therapeutics, Inc7$148
Avion Pharmaceuticals8$138
Johnson & Johnson(2 entities)7$137
MDD US Operations, LLC7$133
Sumitomo Pharma America, Inc.1$123
Kyowa Kirin, Inc.6$104
Corium, LLC4$102
TG Therapeutics, Inc.4$102
E.r. Squibb & Sons, L.L.C.5$95
Upsher-smith Laboratories LLC6$85
Grifols USA, LLC4$82
Jazz Pharmaceuticals Inc.3$73
Livanova USA, Inc.2$64
Sanofi-aventis U.S. LLC3$53
Supernus Pharmaceuticals, Inc.2$40
Ipsen Biopharmaceuticals, Inc2$36
Tanabe Pharma America, Inc.1$32
Revance Therapeutics, Inc.1$29
Insightec,inc2$28
Springworks Therapeutics, Inc.1$25
Akcea Therapeutics, Inc.1$21
C2n Diagnostics, LLC1$20
Advanced Respiratory, Inc1$17
Neurelis, Inc.1$17
Scilex Pharmaceuticals Inc.1$17
Almatica Pharma LLC1$17
Sandoz1$16
Impel Pharmaceuticals Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,563 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$383,668
Medicare patients
772
Services billed
7,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5036$702,477
GammakedImmune Globul G/Gly/Iga Avg 4628$279,235
Nurtec OdtRimegepant Sulfate25$29,121
QuliptaAtogepant22$23,591
Aimovig AutoinjectorErenumab-Aooe17$12,983
UbrelvyUbrogepant11$11,833
Emgality PenGalcanezumab-Gnlm14$11,791
Gabapentin300$5,491
Levetiracetam181$5,408
Carbidopa-LevodopaCarbidopa/Levodopa118$4,294
Duloxetine Hcl165$4,160
Memantine Hcl155$3,934
Entacapone25$3,517
Donepezil Hcl295$3,415
Pyridostigmine Bromide31$1,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$331$731,59961 claims
AbbVieQulipta, Ubrelvy$1,761$35,42433 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$230$2,89544 claims
Upsher-smith Laboratories LLCTopiramate$85$1,254115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →